Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

Monday, March 23, 2026

AI Briefing

Estrella Immunopharma, Inc. receives initiating coverage with a $12.00/Share valuation from Zacks Small-Cap Research.
The coverage report highlights the Company's differentiated immunotherapy pipeline.
Estrella Immunopharma is developing CD19 and CD22-targeted ARTEMIS T-cell therapies for cancer and autoimmune diseases.